Lee’s Pharmaceutical of Hong Kong and Beijing Shenogen Pharma agreed to develop their two separate clinical-stage liver cancer drug candidates as a compound regimen in China. Lee's is currently conducting a Phase III trial of Pexa-Vec, an oncolytic virus; and Shenogen is testing icaritin, a purified traditional Chinese medicine, in a Phase II trial. Lee's and Shenogen said the two drugs have shown synergistic effects in mouse models. Ultimately, the two companies hope to expand the indications for the joint regimen to include other late-stage cancers.
